Altimmune to Participate at Two Upcoming Investor Conferences
JMP Securities Life Sciences Conferencein New York, NY Tuesday, May 16, 2023
Fireside chat at
9:00 am Eastern Time
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.
- Piper Sandler Spring Biopharma Symposium in
Boston, MA Thursday, May 18, 2023
One-on-one meetings only
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Altimmune Investor & Media Contact:
Chief Financial Officer
Source: Altimmune, Inc